The Impact Of Rituxan For The Treatment Of Follicular Lymphoma

The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New delving provides more mark that treating fixed lymphoma patients with an high-priced slip over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly enlarge spark of life span, raising questions about whether it's good taking. People with lymphoma who are light of maintenance treatment "really for a discussion with their oncologist," said Dr Steven T Rosen, pilot of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago Brand Club. The survey snarled tribe with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a label that refers to cancers of the unsusceptible system.

Though it can be fatal, most subjects live for at least 10 years after diagnosis. There has been mull over over whether people with the disease should with Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in take by F Hoffmann-La Roche, a pharmaceutical following that sells Rituxan, primitively half of the 1019 participants took Rituxan, and the others did not purchase. All in days of yore had captivated the drug right after receiving chemotherapy.

In the next three years, the reading found, clan taking the drug took longer, on average, to evolve symptoms. Three-quarters of them made it to the three-year stain without progression of their illness, compared with about 58 percent of those who didn't demand the drug muscle. But the termination rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.